Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen u.S. Plan — Investments at Fair Value ($M) ($M)
Form 11-K Amgen Retirement and Savings Plan (U.S.)
Latest, FY2025
8,166
Period ended Dec 31, 2025
Change on a year earlier
+16.1%
7,033 in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Amgen U.S. Plan — Investments at Fair Value ($M) ($M), annual FY2017–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/plan_us_inv_fv
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.